Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today announced the presentation of ...

Not everyone with mycosis fungoides experiences all of these symptoms. Some people may only have a rash without progressing to the next stages. Sézary syndrome also involves cancerous lymphocytes ...

By far the most common variant of CTCL is mycosis fungoides and its leukemic variant Sézary syndrome. Mycosis fungoides imposes a tremendous physical as well as psychological burden for patients ...

Innate Pharma has claimed long-term data from a phase 2 study show its anti-KIR3DL2 antibody has a “sustained effect” against ...

Mycosis fungoides, and Sézary syndrome, its leukemic variant, are the most common CTCL subtypes. The overall 5-year survival rate, which depends in part on disease subtype, is approximately 10% for ...

Pembrolizumab demonstrated clinical activity in patients with mycosis fungoides (MF) and Sézary syndrome (SS), the most common subtypes of cutaneous T-cell lymphoma (CTCL), with nearly half of ...

Although the environmental and infectious triggers of cutaneous T-cell lymphomas have not been well explored, pathogenesis theories for mycosis fungoides and Sézary syndrome include upregulation ...

Second- and third-line treatment for adults with mycosis fungoides or Sézary syndrome reimbursed by Croatia's National Health Insurance Fund (NHIF), effective as of 15th November 2024. Bulgaria's ...

Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented at the ASCO Annual Meeting 2025. Long-term follow-up data from ...

Long term follow-up data from the TELLOMAK Phase 2 trial in Sézary syndrome (SS) and mycosis fungoides (MF) will be presented at the ASCO Annual Meeting 2025. Long-term follow-up data from ...